The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Inception Date: 19/06/2006
Primary Benchmark: S&P Pharms Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
|ZTS||Zoetis Inc. Class A||5.12 %|
|BMY||Bristol-Myers Squibb Company||4.83 %|
|NKTR||Nektar Therapeutics||4.82 %|
|MYL||Mylan N.V.||4.75 %|
|JAZZ||Jazz Pharmaceuticals plc||4.74 %|
|PFE||Pfizer Inc.||4.62 %|
|MRK||Merck & Company Inc. (new)||4.44 %|
|PRGO||Perrigo Company plc||4.33 %|
|JNJ||Johnson & Johnson||4.20 %|
|AGN||Allergan plc||4.18 %|
|XLV||SPDR Select Sector Fund - Heal..||0.14 %||
|VHT||Vanguard Health Care||0.10 %||
|XBI||SPDR Series Trust S&P Biotech||0.35 %||
|IYH||iShares U.S. Healthcare||0.44 %||
|IHI||iShares U.S. Medical Devices||0.44 %||
|IXJ||iShares Global Healthcare||0.48 %||
|FBT||First Trust Amex Biotech Index..||0.56 %||
|FHLC||Fidelity MSCI Health Care Inde..||0.08 %||
|FXH||First Trust Health Care AlphaD..||0.62 %||
|HQH||Tekla Healthcare Investors||0.00 %||
|Market Performance vs.
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||24.50%||18%||F||26%||F|
|Risk Adjusted Return||23.43%||14%||F||29%||F|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.